Author:
Daikos George L.,Tsaousi Sophia,Tzouvelekis Leonidas S.,Anyfantis Ioannis,Psichogiou Mina,Argyropoulou Athina,Stefanou Ioanna,Sypsa Vana,Miriagou Vivi,Nepka Martha,Georgiadou Sarah,Markogiannakis Antonis,Goukos Dimitris,Skoutelis Athanasios
Abstract
ABSTRACTCarbapenemase-producingKlebsiella pneumoniaestrains (CP-Kps) are currently among the most important nosocomial pathogens. An observational study was conducted during 2009 to 2010 in two hospitals located in a high-prevalence area (Athens, Greece). The aims were (i) to evaluate the clinical outcome of patients with CP-Kp bloodstream infections (BSIs), (ii) to identify predictors of mortality, and (iii) to evaluate the various antibiotic schemes employed. A total of 205 patients with CP-Kp BSIs were identified: 163 (79.5%) were infected with KPC or KPC and VIM, and 42 were infected with VIM producers. For definitive treatment, 103 patients received combination therapy (two or more active drugs), 72 received monotherapy (one active drug), and 12 received therapy with no active drug. The remaining 18 patients died within 48 h after the onset of bacteremia. The all-cause 28-day mortality was 40%. A significantly higher mortality rate was observed in patients treated with monotherapy than in those treated with combination therapy (44.4% versus 27.2%;P= 0.018). The lowest mortality rate (19.3%) was observed in patients treated with carbapenem-containing combinations. In the Cox proportion hazards model, ultimately fatal disease (hazards ratio [HR], 3.25; 95% confidence interval [CI], 1.51 to 7.03;P= 0.003), the presence of rapidly fatal underlying diseases (HR, 4.20; 95% CI, 2.19 to 8.08;P< 0.001), and septic shock (HR, 2.15; 95% CI, 1.16 to 3.96;P= 0.015) were independent predictors of death. Combination therapy was strongly associated with survival (HR of death for monotherapy versus combination, 2.08; 95% CI, 1.23 to 3.51;P= 0.006), mostly due to the effectiveness of the carbapenem-containing regimens.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference33 articles.
1. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions;Tzouvelekis;Clin. Microbiol. Rev.,2012
2. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases;Munoz-Price;Lancet Infect. Dis.,2013
3. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline;Livermore;Int. J. Antimicrob. Agents,2011
4. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase;Chiu;PLoS One,2013
5. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital;Mammina;Euro Surveill.,2012
Cited by
489 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献